ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance
| Autor: | B. Pinto-Simões, Fabíola Attié de Castro, Aline Fernanda Ferreira, Cristina Ivan, Dimas Tadeu Covas, Nelson Hamerschlak, Simone Kashima, George A. Calin, Luciana Ambrósio, L. G. Moura, I. Tojal |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Adult
Male Adolescent medicine.drug_class Fusion Proteins bcr-abl Antineoplastic Agents Apoptosis Philadelphia chromosome Tyrosine-kinase inhibitor Piperazines Young Adult hemic and lymphatic diseases Cell Line Tumor Leukemia Myelogenous Chronic BCR-ABL Positive medicine Humans Kinase activity Phosphorylation Proto-Oncogene Proteins c-abl neoplasms Molecular Biology Protein Kinase Inhibitors Aged Neoplasm Staging Chemistry Gene Expression Regulation Leukemic EXPRESSÃO GÊNICA Imatinib Cell Biology Hematology Middle Aged medicine.disease Dasatinib MicroRNAs Imatinib mesylate Pyrimidines Treatment Outcome Nilotinib Drug Resistance Neoplasm Case-Control Studies Benzamides Cancer research Disease Progression Imatinib Mesylate Molecular Medicine Female Tyrosine kinase medicine.drug |
| Zdroj: | Repositório Institucional da USP (Biblioteca Digital da Produção Intelectual) Universidade de São Paulo (USP) instacron:USP |
| ISSN: | 1096-0961 |
| Popis: | Background Chronic myeloid leukemia (CML) is a myeloproliferative disease characterized by the presence of Philadelphia chromosome (Ph) leading to expression of a BCR–ABL1 fusion oncogene. The BCR–ABL protein has a constitutive tyrosine kinase activity which is responsible for CML pathogenesis by promoting cell apoptosis resistance; however, the cellular and molecular mechanisms associated with BCR–ABL expression and apoptosis impairment in CML leukemic cells have not been fully elucidated. Methods This study evaluated apoptomiRs and their predicted apoptotic genes in BCR–ABL+ cells from patients in different phases of CML treated with tyrosine kinase inhibitor (TKI) according to their imatinib (IM) response by qPCR. Phosphotyrosine and c-ABL expressions in HL-60.BCR–ABL cells treated with TKI were done by Western blot. Results We found that dasatinib (DAS) modulated miR-let-7d, miR-let-7e, miR-15a, miR-16, miR-21, miR-130a and miR-142-3p expressions while IM modulated miR-15a and miR-130a levels. miR-16, miR-130a and miR-145 expressions were modulated by nilotinib (NIL). We observed higher miR-15a, miR-130b and miR-145; and lower miR-16, miR-26a and miR-146a expressions in CML-CP in comparison with controls. CML-AP patients showed low miR-let-7d, miR-15a, miR-16, miR-29c, miR-142-3p, miR-145, and miR-146a levels in comparison with CML-CP. We noted that the miR-26a, miR-29c, miR-130b and miR-146a expressions were downregulated in IM resistant patients in comparison with IM responsive patients. Conclusions This study showed the modulation of apoptomiRs by BCR–ABL kinase activity and the deregulation of apoptomiRs and their predicted apoptotic target genes in different CML phases and after treatment with TK inhibitors. ApoptomiRs may be involved in the BCR–ABL+ cell apoptosis regulation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect